Heroes for Hallie Grace: Turning Grief into Action

In this episode, Jason Hawkes, MD, returns to discuss the evolving role of translational dermatology in bringing scientific discoveries closer to patient care. He shares how advances in immunology and […]

In this episode of PeDRA Pearls, we explore the discovery of Bachmann-Bupp syndrome and the remarkable collaboration that transformed a single patient observation into a growing body of research and […]

In this episode of PeDRA Pearls, host Jenn Dawson welcomes Mitchell Hanson, MD, MPH, PeDRA’s new Education Fellow, for a conversation about connection, service, and intentionality in pediatric dermatology. Mitchell […]

Research in Action: Advancing Care for Epidermolysis Bullosa (EB) is a new virtual education series chaired by Irene Lara-Corrales, MD, of the University of Toronto, and Marissa Perman, MD, of the […]

Tune in to hear Dr. Cathryn Sibbald and Dr. Ilka Netravali, leaders of PeDRA’s Hair Disorders Focused Study Group, explore how pediatric hair disorders research is evolving beyond alopecia areata. […]

PeDRA Biostatistician Amy Buros Stein, PhD, provides a detailed presentation on how to prepare for your first consultation with a biostatistician, including key considerations to address before launching a research […]

In this episode, host Jenn Dawson talks with Dr. Dawn Davis, Dr. Amy Paller, and Dr. Larry Eichenfield about the newly published pediatric atopic dermatitis guidelines and what they mean […]

PeDRA was proud to be part of the 2026 Society for Investigative Dermatology (SID) Annual Meeting. From cutting-edge research presentations to meaningful conversations with leaders in the field, the meeting highlighted […]

Skin reactions during pediatric cancer treatment can be painful, stigmatizing, and sometimes threaten a child’s ability to stay on therapy. In this episode of PeDRA Pearls, Dr. Christina Boull and Dr. Rebecca Levy discuss PeDRA’s Skin Tumors and Reactions to Cancer Therapies (STARC) Focused Study Group and its work to prevent, recognize, and manage these toxicities. They highlight multicenter efforts spanning photosensitivity prevention, survivorship outcomes, and targeted therapy side effects—including MEK inhibitor–associated mucocutaneous toxicities—plus the need for stronger derm–onc collaboration, better trial reporting, and evidence-based consensus guidelines. Keywords: Skin Cancer, MEK Inhibitors, Consensus Guidelines, Photosensitivity

In her final episode as guest host, PeDRA Fellow Hannah Chang talks with Dr. Andrea Zaenglein and Dr. Jonette Keri about the 2023 PeDRA consensus recommendations on using combined oral […]

In this episode, we bring together two leaders in pediatric dermatology research to explore the work of PeDRA’s Connective Tissue and Autoinflammatory Disorders Focused Study Group. Dr. Kalyani Marathe, the […]

In this special episode of PeDRA Pearls, host Jenn Dawson speaks with PeDRA Fellow Hannah Chang as she reflects on her two-year fellowship experience. Hannah shares highlights from recent conferences, […]